AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Glucose-6-phosphate exchanger SLC37A4 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Glucose-6-phosphate exchanger SLC37A4 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Glucose-6-phosphate exchanger SLC37A4, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Glucose-6-phosphate exchanger SLC37A4. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Glucose-6-phosphate exchanger SLC37A4. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Glucose-6-phosphate exchanger SLC37A4 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Glucose-6-phosphate exchanger SLC37A4
partner:
Reaxense
upacc:
O43826
UPID:
G6PT1_HUMAN
Alternative names:
Glucose-5-phosphate transporter; Glucose-6-phosphate translocase; Solute carrier family 37 member 4; Transformation-related gene 19 protein
Alternative UPACC:
O43826; O96016; Q5J7V4; Q9UI19; Q9UNS4
Background:
The Glucose-6-phosphate exchanger SLC37A4, also known as Glucose-5-phosphate transporter and Glucose-6-phosphate translocase, plays a pivotal role in glucose homeostasis. It functions as an inorganic phosphate and glucose-6-phosphate antiporter in the endoplasmic reticulum, crucial for glycogenolysis and gluconeogenesis processes.
Therapeutic significance:
SLC37A4's dysfunction is linked to metabolic disorders such as Glycogen storage disease types 1B, 1C, and 1D, and Congenital disorder of glycosylation 2W, characterized by hypoglycemia, hepatomegaly, and growth retardation. Targeting SLC37A4 could offer novel therapeutic avenues for these conditions.
